Savanna Kirk
Family · San Francisco, CANPI 1588379168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 608 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Viiv Healthcare Company at 27.2% of the total. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 608 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$2K
- EMD Serono, Inc.$2K
- AbbVie$1K
- AstraZeneca$942
- Theratechnologies Inc.$721
- plus $5K from 29 others
What the payments were for
- Food & beverage$15,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 151 | $4,197 |
| Gilead | 67 | $1,568 |
| EMD Serono, Inc. | 69 | $1,510 |
| AbbVie | 60 | $1,391 |
| AstraZeneca | 36 | $942 |
| Theratechnologies Inc. | 25 | $721 |
| Merck | 22 | $663 |
| Novo Nordisk | 34 | $564 |
| Pfizer | 20 | $410 |
| Lilly USA, LLC | 14 | $385 |
| Napo Pharmaceuticals Inc | 15 | $383 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $330 |
| Axsome Therapeutics, Inc. | 3 | $312 |
| Antares Pharma, Inc. | 11 | $258 |
| Lundbeck LLC | 7 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $195 |
| Boehringer Ingelheim | 7 | $187 |
| Otsuka America Pharmaceutical, Inc. | 7 | $181 |
| Collegium Pharmaceutical, Inc. | 8 | $162 |
| Exact Sciences | 4 | $108 |
| Boston Scientific | 1 | $102 |
| GSK | 4 | $89 |
| Bausch Health US, LLC | 4 | $85 |
| Kowa Pharmaceuticals America, Inc. | 4 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Amgen | 2 | $52 |
| Verity Pharmaceuticals Inc. | 2 | $50 |
| Indivior Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $40 |
| Astellas Pharma US Inc | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $23 |
| Novartis | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,453 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 21 | $331,737 |
| TivicayDolutegravir Sodium | 28 | $110,288 |
| DescovyEmtricitabine/Tenofov Alafenam | 20 | $53,964 |
| ZenpepLipase/Protease/Amylase | 12 | $52,186 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $51,546 |
| OzempicSemaglutide | 48 | $50,743 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $47,006 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $38,243 |
| PrezistaDarunavir | 12 | $26,347 |
| IsentressRaltegravir Potassium | 12 | $23,482 |
| MounjaroTirzepatide | 18 | $19,713 |
| RybelsusSemaglutide | 20 | $18,909 |
| JardianceEmpagliflozin | 20 | $12,603 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $8,280 |
| Testosterone | 43 | $7,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $1,510 | $331,73721 claims |
| Viiv Healthcare CompanyTivicay, Dovato | $4,197 | $161,83441 claims |
| GileadDescovy, Genvoya | $1,568 | $100,97032 claims |
| Novo NordiskOzempic, Rybelsus | $564 | $69,65268 claims |
| MerckIsentress, Janumet Xr | $663 | $31,76323 claims |
| Lilly USA, LLCMounjaro | $385 | $19,71318 claims |
| Boehringer IngelheimJardiance | $187 | $12,60320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Francisco
- Gabriel SchwartzSan Francisco$166K
- Annika EhrlichSan Francisco$128K
- Monica VolzSan Francisco$96K
- Bethany KinseySan Francisco$33K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.